MabVax now announces plans to sell public offering of 2,189,781 units

Bookrunner Laidlaw raises funds for general corporate purposes

By Devika Patel

Knoxville, Tenn., Sept. 28 – MabVax Therapeutics Holdings, Inc. will sell 2,189,781 units in its public offering with a 30-day greenshoe of 164,234 units, according to a Form S-1/A filed Monday with the Securities and Exchange Commission. The company has registered up to $5.52 million of underlying stock for the deal, which was announced as a stock sale on June 8.

The units consist of one share and a half-share warrant; the warrants will exercisable at 120% of the per-unit price.

Laidlaw & Co. (UK) Ltd. is the bookrunning manager.

Proceeds will be used for working capital and general corporate purposes.

The biopharmaceutical company is based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.